Evidence map›Paper›PMID 26998137›Full record

ArticleOncology letters2016

Small bowel adenocarcinoma arising in a patient with hereditary hemorrhagic telangiectasia: A case report.

Yuichiro Yoshioka, Hiroaki Nozawa, Junichiro Tanaka, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Shinsuke Kazama, Hironori Yamaguchi and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Yuichiro YoshiokaDepartment of Surgical Oncology, University of Tokyo, Tokyo 113-8655, Japan.
Hiroaki NozawaDepartment of Surgical Oncology, University of Tokyo, Tokyo 113-8655, Japan.
Junichiro TanakaDepartment of Surgical Oncology, University of Tokyo, Tokyo 113-8655, Japan.
Takeshi NishikawaDepartment of Surgical Oncology, University of Tokyo, Tokyo 113-8655, Japan.
Toshiaki TanakaDepartment of Surgical Oncology, University of Tokyo, Tokyo 113-8655, Japan.
Tomomichi KiyomatsuDepartment of Surgical Oncology, University of Tokyo, Tokyo 113-8655, Japan.
Kazushige KawaiDepartment of Surgical Oncology, University of Tokyo, Tokyo 113-8655, Japan.
Keisuke HataDepartment of Surgical Oncology, University of Tokyo, Tokyo 113-8655, Japan.
Shinsuke KazamaDepartment of Surgical Oncology, University of Tokyo, Tokyo 113-8655, Japan.
Hironori YamaguchiDepartment of Surgical Oncology, University of Tokyo, Tokyo 113-8655, Japan.
Soichiro IshiharaDepartment of Surgical Oncology, University of Tokyo, Tokyo 113-8655, Japan.
Eiji SunamiDepartment of Surgical Oncology, University of Tokyo, Tokyo 113-8655, Japan.
Joji KitayamaDepartment of Surgical Oncology, University of Tokyo, Tokyo 113-8655, Japan.
Toshiaki WatanabeDepartment of Surgical Oncology, University of Tokyo, Tokyo 113-8655, Japan.
The University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with hereditary hemorrhagic telangiectasia (HHT) are reportedly at a lower overall risk of malignancies, and small bowel adenocarcinoma (SBA) arising in a HHT patient is extremely rare. In this study, the case of a 37-year-old female with HHT who developed a poorly differentiated jejunal adenocarcinoma five years after ileocecal resection for multiple colonic adenomas is presented. The patient underwent curative resection of the cancer invading the ileum and the mesentery of the transverse colon, but had to overcome critical complications perioperatively, stemming from HHT-associated peripheral capillary dilatation and arteriovenous malformation, including nosebleeds and possible infusion-induced air embolism through pulmonary shunts. The patient subsequently received adjuvant chemotherapy including capecitabine and oxaliplatin for 6 months, and currently remains alive without any evidence of recurrence 12 months after the second surgery. This patient with SBA was an instructive case demonstrating the necessity of careful attention during major surgery in HHT.

Indexed as

chemotherapycomplicationshereditary hemorrhagic telangiectasiasmall bowel adenocarcinomasurgical management

Identifiers

PMID26998137
PMCPMC4774470
OpenAlexW2254233639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.